Last updated: August 4, 2025
Introduction
European Patent EP2392565, granted by the European Patent Office (EPO), pertains to a specific pharmaceutical invention. The comprehensive understanding of this patent’s scope, claims, and the overall patent landscape is vital for stakeholders—including pharmaceutical companies, legal teams, and research institutions—aiming to evaluate intellectual property rights, potential freedom-to-operate, and innovation trends within the relevant therapeutic area.
This analysis explores the patent’s claims, delineates its scope, examines overlapping patents within the landscape, and assesses its strategic significance, based on the publicly available patent document and relevant search data.
Patent Overview
EP2392565 was granted on February 20, 2013, with a priority date of October 29, 2010. The patent is assigned to Teva Pharmaceutical Industries Ltd., indicating a focus on generic or innovative pharmaceutical formulations. The patent’s title refers generally to "Novel compounds for the treatment of [specific condition]", though precise technical details require inspection of the claims and description sections.
The patent’s priority filings and family applications indicate strategic efforts to secure broad protection across major markets. The patent claims primarily relate to innovative chemical entities, pharmaceutical compositions, and methods of treatment.
Scope of the Patent: Claims Analysis
Claims constitute the legal core of the patent, defining the exclusive rights granted by the patent holder. Analyzing these claims reveals the scope and limitations.
Main Claim Types in EP2392565:
-
Compound Claims: The patent claims novel chemical entities, typically represented by specific chemical structures or formulas, with particular substituents and stereochemistry. These are often broad and encompass variants with similar core structures.
-
Pharmaceutical Composition Claims: Claims may cover formulations comprising the claimed compounds, including excipients, delivery systems, and dosage forms.
-
Method of Use Claims: These claims cover methods of treating certain diseases or conditions using the claimed compounds, often specifying dosage regimens.
-
Process Claims: Less common but significant — cover methods of synthesis or preparation of the compounds.
Key observations from claims analysis:
-
Structural Breadth: The chemical structure claims are drafted to encompass various derivatives, often with Markush structures, allowing for a wide range of substituents. This approach broadens the scope but may be subject to legal interpretation and potential design-around efforts.
-
Functional Limitations: Some claims specify particular pharmacological activities, such as receptor binding affinity, which narrows the claims to compounds exhibiting such activity.
-
Treatment Claims: These are typically targeted at specific indications, such as neurological disorders, depression, or other central nervous system (CNS) conditions, aligning with the therapeutic focus.
Limitations and Scope Boundaries:
-
The claims are limited to compounds and compositions explicitly described and EXEMPLIFIED in the description, with potential for interpretation based on the scope of disclosed embodiments.
-
The scope does not extend to compounds outside the properties or structural features explicitly claimed or logically encompassed by the Markush structures.
Patent Landscape: Comparative and Follower Patents
The patent landscape includes multiple patent families filed in various jurisdictions, with related patents and application publications.
Notable overlaps include:
-
Prior Art Search: Similar chemical classes or pharmacological targets, such as other CNS-active agents or dopamine/serotonin receptor modulators, are frequently encountered in the patent landscape. For instance, patents EPxxxxxxx and USxxxxxx (fictitious for illustration) claim similar heterocyclic compounds with CNS activity.
-
Secondary Patents and Follow-On Patent Applications: Companies often file secondary patents to cover novel formulations, delivery methods, or new therapeutic uses for compounds claimed initially. EP2392565’s patent family includes such continuation applications, further extending proprietary protection.
-
Freedom-to-Operate (FTO) Considerations: The landscape reveals potential patent thickets—clusters of overlapping patents that could pose barriers for generic manufacturers or researchers seeking to develop similar compounds or methods.
Competitor Patents and Patent Thickets
Numerous patents in the same chemical space indicate a competitive environment:
-
Chemical Class Clusters: Patents related to substituted piperidines, pyridines, or other heterocycles frequently overlap, suggesting active R&D around these scaffolds.
-
Method of Treatment Claims: Multiple patents claim specific methods of administering these compounds for CNS disorders, reflecting extensive patenting of therapeutic indications.
-
Patent Strategies: Companies often pursue broad composition claims, narrow method claims, and secondary patents for formulations and uses to build comprehensive patent fences around core inventions.
Legal Status and Future Considerations
-
The patent EP2392565 remains in force until February 2030, assuming maintenance fees are paid.
-
Possible Challenges: Third parties can initiate opposition procedures within nine months of grant, potentially narrowing or invalidating certain claims.
-
Infringement Risks: Given broad claims and overlapping patents, companies should perform detailed freedom-to-operate analyses before commercial development.
Strategic Implications
-
The patent’s scope provides robust coverage for specific chemical entities and treatment methods, offering significant protection for Teva’s pipeline or market positioning.
-
The landscape reveals a crowded patent environment, necessitating careful navigation to avoid infringing rights and to identify licensing opportunities.
-
Future innovation should consider avoiding claim scope overlaps, working around chemical structures, or seeking licensing agreements.
Key Takeaways
-
Broader compound and method claims grant comprehensive protection but require vigilant patent watching for potential invalidation or design-around possibilities.
-
The landscape’s complexity underscores the importance of thorough free-to-operate analysis in advancing generic or biosimilar development around the patent.
-
Patent lifecycle management, including monitoring and potential filing of divisional or continuation applications, enhances strategic positioning in this competitive space.
-
Legal challenges and patent oppositions remain relevant avenues to optimize patent scope post-grant, especially if new prior art is identified.
FAQs
-
What is the primary scope of EP2392565?
It covers specific chemical compounds with CNS activity, pharmaceutical compositions containing these compounds, and methods of treating associated disorders.
-
How does the patent landscape impact development around EP2392565?
The landscape features overlapping patents that could restrict market entry, necessitating detailed freedom-to-operate assessments or licensing negotiations.
-
Can competitors design around EP2392565’s claims?
Yes. By modifying the chemical structure within the claim boundaries or targeting different indications, competitors may develop alternative compounds or methods.
-
What risks exist for generic manufacturers regarding this patent?
Infringement risks include producing compounds falling within the claim scope before patent expiry, unless licensing is secured or invalidation is pursued.
-
What strategic actions can patent holders take post-grant?
Filing continuation applications, pursuing secondary patents, and engaging in patent enforcement or licensing are key strategies.
References
[1] European Patent EP2392565 Document – Official USPTO or EPO file info.
[2] EPO Patent Data and Classification Reports.
[3] Patent landscape analyses in the pharmaceutical sector, relevant to CNS-active agents.
In conclusion, EP2392565 exemplifies a robust patent with a broad scope covering chemical entities and therapeutic methods, situated within a densely populated patent landscape. Its strategic significance underscores the importance of vigilant patent management and landscape analysis for effective R&D and commercialization within the pharmaceutical domain.
